Christina Poh

Also affiliated with Fred Hutch Cancer Center, City of Hope

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma”.

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Blood(2023)10.1182/blood.2022019254

N/A

1.4DataRank · unranked

39 citations

Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman +21 more

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Advances(2024)10.1182/bloodadvances.2024014455

N/A

0.360DataRank · unranked

10 citations

Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz‐Maldonado, Aya Albittar, Natalie Wuliji +28 more

Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality

TH Open(2020)10.1055/s-0040-1718883

N/A

0DataRank · unranked

13 citations

Ann Brunson, Theresa H.M. Keegan, Ted Wun, Anjlee Mahajan, Christina Poh

A phase 2 study of frontline pembrolizumab in follicular lymphoma

eJHaem(2024)10.1002/jha2.1029

N/A

0DataRank · unranked

0 citations

Songli Zhu, Ted Gooley, Taranjit S. Gujral, Ryan C. Lynch, Christina Poh +5 more

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Blood Advances(2025)10.1182/bloodadvances.2025016845

N/A

0DataRank · unranked

2 citations

Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert +20 more